Featured Research

from universities, journals, and other organizations

How long should HCV treatment last? Study suggests answers are complex

Date:
May 28, 2014
Source:
University at Buffalo
Summary:
As new treatments for hepatitis C virus (HCV) are approved, biomedical scientists are exploring their mechanisms and what they reveal about the virus. A new report is the first to report real-time tracking of viral decay in the liver and blood in 15 patients with HCV. "Our findings begin to define for how long patients may need to be treated in order to achieve viral eradication," explained the lead researcher.

The study, led by Talal, is the first to report real-time tracking of viral decay in the liver and blood of patients with HCV.
Credit: Image courtesy of University at Buffalo

As new treatments for hepatitis C virus (HCV) are approved, biomedical scientists are exploring their mechanisms and what they reveal about the virus. An online publication this month in Hepatology is the first to report real-time tracking of viral decay in the liver and blood in 15 patients with HCV.

Related Articles


Led by Andrew H. Talal, MD, University at Buffalo professor of medicine in the Division of Gastroenterology, Hepatology and Nutrition and corresponding author, the study is the first to trace in real-time how the drug telaprevir inhibits viral replication in the liver and how it clears HCV from infected cells and plasma of infected patients.

The study was sponsored by Vertex Pharmaceuticals, which makes telaprevir, an HCV protease inhibitor.

"Our findings begin to define for how long patients may need to be treated in order to achieve viral eradication," explained Talal.

"There has been no precise definition of the duration of treatment based upon serial measurements of the virus in the liver," said Talal. "This is the first time that serial measurements in the liver have been performed during antiviral therapy."

In previous studies, a more invasive procedure -- core needle biopsy -- was used to sample the liver in HCV infection. In the current study, fine needle aspiration was used; this method is better tolerated by patients and allows for repeated sampling at more time points than core needle biopsy.

"Fine needle aspiration enables us to sample the liver repeatedly during the course of treatment, to better understand what's happening with the virus, how these drugs work and how to tailor therapy to the patient," Talal explained.

In the study, conducted at Weill Cornell Medical College in New York City, 15 patients with chronic HCV infection were treated with telaprevir-based triple therapy (consisting of telaprevir/pegylated interferon alfa/ribavirin), an HCV treatment regimen that was approved by the Food and Drug Administration in 2011.

Fine needle aspiration of the liver was performed before treatment on all 15 patients and at these intervals following treatment: ten hours, on days 4 and 15, and at week eight. Viral kinetics, resistance patterns, drug concentrations and host transcription profiles were measured.

Of particular interest were the study's findings regarding the rate of decay for viral ribonucleic acid (RNA), an indicator of how quickly the virus is being eradicated. "We found that HCV RNA decay in the liver lagged behind that in the peripheral blood, which has implications for how long the virus may persist in the body and the possible duration of treatment needed," said Talal.

They also found higher levels of the drug in blood than in the liver.

"These findings can affect the duration of therapy," said Talal, adding that they can also help to identify when drug-resistant variants of the virus emerge in blood and in the liver.

The findings also may have relevance to the development of other methods of treating HCV, such as vaccines that could be used to control the infection, he added.


Story Source:

The above story is based on materials provided by University at Buffalo. The original article was written by Ellen Goldbaum. Note: Materials may be edited for content and length.


Journal Reference:

  1. Andrew H Talal, Rositsa B Dimova, Eileen Z. Zhang, Min Jiang, Marina S. Penney, James C. Sullivan, Martyn C. Botfield, Ananthsrinivas Chakilam, Rishikesh Sawant, Christine M. Cervini, Marija Zeremski, Ira M. Jacobson, Ann D. Kwong. Telaprevir-based treatment effects on hepatitis C virus in liver and blood. Hepatology, 2014; DOI: 10.1002/hep.27202

Cite This Page:

University at Buffalo. "How long should HCV treatment last? Study suggests answers are complex." ScienceDaily. ScienceDaily, 28 May 2014. <www.sciencedaily.com/releases/2014/05/140528145819.htm>.
University at Buffalo. (2014, May 28). How long should HCV treatment last? Study suggests answers are complex. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2014/05/140528145819.htm
University at Buffalo. "How long should HCV treatment last? Study suggests answers are complex." ScienceDaily. www.sciencedaily.com/releases/2014/05/140528145819.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins